The main idea here is that the Friedman test serves as the nonparametric counterpart to the one-way repeated measures ANOVA. It is used when you have more than two related or matched conditions measured on the same subjects and you cannot assume that the data are normally distributed. Instead of using raw scores, the Friedman test works with ranks across those related conditions, preserving the within-subjects nature of the design while relaxing the normality assumption. This makes it the appropriate nonparametric alternative for detecting overall differences across multiple related conditions. The other options don’t fit because the independent t-test compares two unrelated groups, and the paired t-test compares two related conditions (only two levels). Two-way ANOVA involves two factors (and can include interactions), whereas Friedman handles a single within-subjects factor with multiple levels. For more than two related conditions with nonparametric data, Friedman is the right choice.

P-values gauge how compatible the observed data are with the null hypothesis. If the p-value is greater than 0.05, we do not have enough evidence to reject the null at the conventional 5% significance level, so the result is not statistically significant. This means the data don’t show a statistically reliable effect at that threshold, not that there is definitely no effect. It could reflect limited sample size or variability rather than a true absence of an effect. It’s also not a direct measure of study power or of how precise the estimate is; a high p-value doesn’t guarantee high power or a narrow confidence interval.

Including all relevant predictive factors during development ensures the rule truly reflects the influences that matter for the outcome. When you develop a CPR, you want the model to account for the key drivers that could change risk; omitting important predictors leaves out pieces of the puzzle, leading to incomplete or biased predictions and poorer performance across settings. By deliberately incorporating all relevant factors identified from evidence, clinical reasoning, and prior research, the rule gains content validity and better generalizability. Other options touch on important aspects of validation and measurement—comparing to a criterion test pertains to external validation, defining predictive factors relates to how they are measured, and having a large enough sample size helps stabilize estimates and prevents overfitting. However, none of these guarantees that every relevant predictive factor is included in the development process the way explicitly including all relevant predictive factors does.

Inter-rater reliability measures how consistently different raters score or classify the same patient. When two or more clinicians independently assess the same person and arrive at similar results, the assessment demonstrates good inter-rater reliability, meaning the rating is not heavily dependent on who does the rating. This matters because it shows the instrument or method yields consistent results across observers. If ratings vary widely between clinicians, reliability is low. For contrast, intra-rater reliability would involve the same clinician rating the same patient on different occasions, emphasizing consistency of one observer. Repeating the same test with the same rater checks test-retest reliability, not agreement between different raters. Testing the patient twice with different index tests relates to concordance between tests, not observer reliability.